GHK-Cu: Compound Profile

GHK-Cu is one of the longest-studied bioactive peptides in human research — the primary literature now spans more than fifty years — and one of the most consistently misframed in popular writing. The molecule is real, the published mechanisms are biologically coherent, and the chronic-wound and dermatological evidence base is more substantive than that of most peptides marketed as “copper peptide.” What that evidence does not establish is a parenteral therapeutic indication. This profile describes the molecule the way the primary literature actually describes it.

Nothing in this article is a recommendation. GHK-Cu is supplied by PepMax under the product slug ghk-cu for laboratory research use only. It is not approved by FDA, EMA, MHRA, Health Canada, or any other regulator we ship to for human or veterinary therapeutic use.

At a glance

The data sheet below summarizes molecular identity. Sequence, formula, and the copper binding constant come from the primary characterization literature, with the binding affinity figure recurring across the Pickart corpus and independent coordination-chemistry reports^[2].

What GHK-Cu is

GHK-Cu is the 1:1 copper(II) chelate of the tripeptide glycyl-L-histidyl-L-lysine. The tripeptide itself is endogenous: it occurs in human plasma, saliva, and urine, and was first isolated from human plasma albumin in 1973 by Loren Pickart, then at the University of California, San Francisco, in the course of experiments on why old human plasma produced different effects on cultured liver cells than young plasma did^[1]. The activity that distinguished young plasma from old plasma was traced to a small peptide; the peptide was the tripeptide GHK; and the activity was strongest when the peptide was complexed with copper.

The molecular identity has three anchor points. The first is the sequence itself (Gly-His-Lys), short enough that it is reproducibly synthesized and unambiguously identified by mass spectrometry. The second is the copper-binding mode: the histidine imidazole, the deprotonated amide nitrogen of the histidine, and the terminal amine of glycine form a square-planar chelate with Cu²⁺, with the lysine side-chain extending outward to interact with downstream targets. The third is thecopper-extraction equilibrium: at physiological pH the GHK–Cu²⁺ binding constant is high enough (log K ≈ 16.4) that GHK can pull copper away from albumin, the major extracellular copper carrier, and deliver it across cell membranes. That equilibrium is what makes GHK behave as a copper-shuttle rather than as a passive chelator.

Proposed mechanisms

Because GHK does not act through a single high-affinity receptor, the mechanism literature describes a constellation of effects that converge on tissue remodeling, antioxidant defense, and gene-expression normalization. Four pathways are most consistently cited.

Copper shuttle

The foundation of the GHK story is its coordination chemistry. At physiological pH, GHK forms a square-planar 1:1 chelate with Cu²⁺ via the histidine imidazole, the deprotonated peptide-bond nitrogen between glycine and histidine, and the glycine α-amine^[2]. The reported binding constant (log K ≈ 16.4) is high enough to extract copper from human serum albumin — the major extracellular copper carrier — and deliver it across membranes. Copper is a required cofactor for enzymes including lysyl oxidase (collagen and elastin cross-linking), superoxide dismutase 1 (cytosolic antioxidant defense), and several mitochondrial oxidases. The copper-shuttle model interprets many of GHK’s downstream effects as consequences of regulated copper delivery to those cofactor pools.

Extracellular matrix synthesis

The most directly characterized cellular effect is the stimulation of extracellular-matrix synthesis in dermal fibroblasts. Maquart and colleagues (1988) demonstrated that GHK-Cu at nanomolar concentrations increased collagen production in cultured human dermal fibroblasts, with a peak response reported at approximately 1 nM^[3]. Subsequent work extended the finding to elastin, glycosaminoglycans (including dermatan and chondroitin sulfates), and the small leucine-rich proteoglycan decorin. The same cell-culture systems have shown coordinated regulation of matrix metalloproteinases (MMP-1, MMP-2) and their tissue inhibitors (TIMP-1, TIMP-2), interpreted in the literature as a remodeling rather than a purely synthetic phenotype^[2].

Antioxidant defense

GHK-Cu has been reported to upregulate antioxidant enzymes — principally superoxide dismutase 1 (SOD1) — and to modulate expression of a broader antioxidant gene cluster^[10]. The mechanistic interpretation is dual: (1) regulated copper delivery supports the catalytic copper centers of cytosolic SOD1 and lysyl oxidase, and (2) the chelate sequesters loose iron and copper that would otherwise drive Fenton chemistry and lipid peroxidation. Anti-inflammatory effects on TNF-α-driven IL-6 secretion in normal human dermal fibroblasts have also been reported^[9].

Gene-expression reset

The most striking, and the most dependent on a single analytical approach, is the gene-expression literature. Pickart and colleagues used the Broad Institute Connectivity Map^[8]— a database that compares transcriptional signatures across small molecules — to compare the GHK-induced transcriptional response to disease and aging signatures. The reported result is reset of more than 4 000 human genes, with directional changes consistent with tissue regeneration and reversal of inflammatory or senescent profiles^[5][7]. The effect is interpreted as coordinated modulation of master regulators including SIRT1 and STAT3. The reader should understand that “reset” in this context is a connectivity-distance metric, not a direct measurement of phenotypic reversal.

Evidence map

The figure below summarizes the published GHK-Cu evidence base by tissue or system. Each row reflects the highest level of evidence we have identified from peer-reviewed sources, not the volume of studies. Where evidence is limited to in vitro or animal models, that is stated explicitly.

Skin and extracellular matrix

The dermal-fibroblast literature is the most developed sub-corpus and the most replicated outside the originating laboratory. The 1988 Maquart paper anchored the peak-collagen-at-1-nM finding^[3]; subsequent work from Maquart’s and other independent French dermatology groups extended it to elastin, dermatan sulfate, chondroitin sulfate, and decorin. Pickart’s 2008 review consolidated the tissue-remodeling framework^[2], and the 2015 BioMed Research International review expanded it to keratinocytes and skin-stem-cell systems^[5]. Topical human studies report improvements in fine-line depth, photo-aging visual scores, and barrier-function parameters, with effect sizes generally modest and study sizes generally small.

Chronic wounds

The most substantive controlled human trial in the GHK-Cu record is Mulder et al. (1994), a randomized, vehicle-controlled Phase II study of topical GHL-Cu (Iamin Gel) in diabetic foot ulcers^[4]. Active treatment was associated with faster ulcer closure than vehicle in the per-protocol analysis. The trial was the lead clinical readout of ProCyte’s wound-healing program. ProCyte subsequently divested the program; no Phase III pivotal trial was reported, and no FDA-approved GHK-Cu wound-care product exists today. Several smaller wound-care reports — ischemic skin grafts, cosmetic post-procedure healing — surround the Phase II in the same era.

Gene-expression and connectivity work

The Connectivity Map analyses are the GHK literature’s most ambitious and most contested findings^[5][7]. The analytical approach compares the transcriptional fingerprint of GHK exposure (in cultured cells) to disease and aging fingerprints in the CMap database^[8], and reports connectivity-distance reductions across thousands of genes. Read carefully, these papers report a reset of transcriptional state in a database comparison, not clinically validated reversal of disease in patients. The interpretation in the secondary literature has occasionally elided the difference. The primary papers are clearer about the limit.

Lung tissue and emphysema signature

Campbell and colleagues (2012) is the most-cited application of CMap-style analysis to GHK in a non-skin tissue^[6]. The authors derived an emphysema-related destruction signature from human COPD lung-tissue transcriptomes and used CMap to identify compounds whose transcriptional signatures opposed it. GHK was a top hit; the in vitro validation (in primary lung fibroblasts) reported partial reversal of the signature. The 2016 Park et al. mouse study extended the framework to LPS-induced acute lung injury, with attenuated injury markers in the GHK-Cu-treated group^[11]. There is no human pulmonary trial.

Hair-follicle research

Most of the clinical hair work was carried by AHK-Cu(alanyl-histidyl- lysine copper), the synthetic analogue developed by ProCyte under the Tricomin brand, rather than by GHK-Cu itself. The mechanistic interpretation in the literature is similar — copper delivery, prolonged anagen, reduced 5α-reductase activity in follicle-cell cultures — but the clinical readouts and patent record sit primarily with the alanine variant^[12]. Effect sizes in the published trials were modest and the program did not displace minoxidil or finasteride as standard therapy.

Human data

The honest summary of the human evidence base is: (1) topical dermatological use accumulated over decades produces a usable real-world safety record at cosmetic dose ranges; (2) one published Phase II trial in chronic diabetic ulcers reported a positive topical efficacy signal that was not advanced to Phase III; (3) hair-loss claims rest primarily on the AHK-Cu Tricomin program, not on GHK-Cu; and (4) no controlled human trial of injected GHK-Cu has been published. The Pickart and Margolina reviews are secondary literature: they synthesize a body of work but do not themselves report new controlled clinical efficacy.

Research timeline

Limitations of the evidence base

Read together, the GHK-Cu literature describes a coherent biology with one of the longest observation periods of any peptide in the research-grade market. Read critically, it has limits that any researcher evaluating the molecule should understand explicitly.

• Originator concentration.A large fraction of the framing literature — the consolidating reviews, the connectivity-map applications, the regenerative- actions synthesis — comes from Pickart and a small group of co-authors with long-standing commercial ties to copper-peptide formulations (Skin Biology). The primary cell-culture and Phase II clinical data are independent; the synthesis on top of them is not. This is structurally similar to the Sikirić/BPC-157 situation and warrants the same critical posture.
• Mechanism-by-association. The four pathways summarized above are observed in different experimental systems, not co-measured in a single integrated study. Coupling the copper-shuttle chemistry to specific transcriptional outcomes via a unified model is a feature of review papers, not of single primary papers.
• Connectivity-Map interpretation.The “>4 000 genes reset” and emphysema-signature-reversal claims are connectivity-distance observations in a transcriptomic database. They are real findings under a defined analytical method; they are not equivalent to controlled trials of phenotypic reversal.
• No phase III, no drug approval. The Iamin Phase II diabetic-ulcer trial is the closest the molecule has come to a controlled human efficacy readout. It did not advance to a pivotal Phase III, and no current GHK-Cu product is FDA-approved for any therapeutic indication.
• Pharmacokinetics in humans. Plasma half-life, bioavailability, tissue distribution, and metabolic fate of injected GHK-Cu in humans are not characterized in peer-reviewed literature. Topical absorption studies exist; parenteral PK does not.
• Copper toxicity ceiling.The molecule’s mechanism centers on copper delivery. At supratherapeutic exposures, copper is hepatotoxic and pro-oxidant. The narrow therapeutic window in animals does not translate cleanly to safe self- administration claims in humans.

Reconstitution & handling

GHK-Cu is supplied as a lyophilized blue-tinted powder — the color comes from the d–d transition of bound Cu²⁺ and is itself a rough indicator that the chelate is copper-loaded. Standard practice across the peptide literature is reconstitution in bacteriostatic water (0.9% benzyl alcohol) for short-term storage in solution, or in sterile water for injectionwhen the bacteriostatic preservative is undesirable for a given research design. Reconstituted GHK-Cu is held at 2–8 °C and protected from light; copper-amine chelates are sensitive to photoreduction and to oxidative degradation in the presence of trace iron. For longer-term storage, the lyophilized powder is held at −20 °C or below. Acidic diluents and reducing agents (e.g. ascorbic acid) can shift the copper coordination equilibrium and should be avoided in the reconstitution medium.

For background on what the analytical numbers on a peptide’s certificate of analysis actually mean — HPLC purity, mass-spectrometric identity confirmation, water content, and what those numbers do and do not tell you about a copper-loaded chelate — see our companion methods articles on what ≥99% purity actually means and how we verify peptide purity.

Further reading

The bibliography below points to the primary papers and reviews referenced in this profile. Where a single number is cited multiple times in the text, it indicates the same source supporting different statements rather than independent corroboration.